TTNP logo

Titan Pharmaceuticals (TTNP) Company Overview

Profile

Full Name:

Titan Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

January 18, 1996

Indexes:

Not included

Description:

Titan Pharmaceuticals (TTNP) is a biopharmaceutical company focused on developing innovative treatments for chronic conditions. They specialize in long-acting drug delivery systems, particularly for opioid addiction and pain management. Their main product, Probuphine, is designed to help patients manage opioid dependence effectively.

Key Details

Price

$4.05

Annual Revenue

$1000.00(-98.33% YoY)

Annual EPS

-$7.41(+51.22% YoY)

Annual ROE

-139.14%

Beta

-0.34

Events Calendar

Earnings

Next earnings date:

May 15, 2025

Recent quarterly earnings:

Jan 3, 2025

Recent annual earnings:

Mar 16, 2017
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 9, 2024

Analyst ratings

Recent major analysts updates

May 26, 22 Maxim Group
Hold
Feb 18, 21 Maxim Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Titan Pharmaceuticals?
  • Does Titan Pharmaceuticals pay dividends?
  • What sector is Titan Pharmaceuticals in?
  • What industry is Titan Pharmaceuticals in?
  • What country is Titan Pharmaceuticals based in?
  • When did Titan Pharmaceuticals go public?
  • Is Titan Pharmaceuticals in the S&P 500?
  • Is Titan Pharmaceuticals in the NASDAQ 100?
  • Is Titan Pharmaceuticals in the Dow Jones?
  • When was Titan Pharmaceuticals's last earnings report?
  • When does Titan Pharmaceuticals report earnings?
  • Should I buy Titan Pharmaceuticals stock now?

What is the ticker symbol for Titan Pharmaceuticals?

The ticker symbol for Titan Pharmaceuticals is NASDAQ:TTNP

Does Titan Pharmaceuticals pay dividends?

No, Titan Pharmaceuticals does not pay dividends

What sector is Titan Pharmaceuticals in?

Titan Pharmaceuticals is in the Healthcare sector

What industry is Titan Pharmaceuticals in?

Titan Pharmaceuticals is in the Biotechnology industry

What country is Titan Pharmaceuticals based in?

Titan Pharmaceuticals is headquartered in United States

When did Titan Pharmaceuticals go public?

Titan Pharmaceuticals's initial public offering (IPO) was on January 18, 1996

Is Titan Pharmaceuticals in the S&P 500?

No, Titan Pharmaceuticals is not included in the S&P 500 index

Is Titan Pharmaceuticals in the NASDAQ 100?

No, Titan Pharmaceuticals is not included in the NASDAQ 100 index

Is Titan Pharmaceuticals in the Dow Jones?

No, Titan Pharmaceuticals is not included in the Dow Jones index

When was Titan Pharmaceuticals's last earnings report?

Titan Pharmaceuticals's most recent earnings report was on Jan 3, 2025

When does Titan Pharmaceuticals report earnings?

The next expected earnings date for Titan Pharmaceuticals is May 15, 2025

Should I buy Titan Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions